Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis
Objectives The response to glucagon-like peptide-1 (GLP-1) analogues for weight loss varies significantly. We investigated the anthropometric, demographic and clinical characteristics associated with total body weight loss (TBWL) from subcutaneous GLP-1 analogue therapy in patients with obesity in a...
Saved in:
Main Authors: | Nadia Khan, Jesse Bittman, Peter Squire, James Naude, Ali Zentner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/15/1/e089477.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Synthesis and Evaluation of Optical and PET GLP-1 Peptide Analogues for GLP-1R Imaging
by: Babak Behnam Azad, et al.
Published: (2015-01-01) -
Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01) -
GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
by: Ioannis Ilias, et al.
Published: (2025-01-01) -
Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01) -
Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes
by: Michela Del Prete, et al.
Published: (2025-01-01)